Loading...
Loading...
ATXI| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 2,823.0K |
| Operating I/L | -2,823.0K |
| Other Income/Expense | 122.0K |
| Interest Income | 52.0K |
| Pretax | -2,701.0K |
| Income Tax Expense | 4,485.0K |
| Net Income/Loss | -7,186.0K |
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the acute/intensive care hospital setting. The company's primary product candidate is intravenous Tramadol, a synthetic dual-acting opioid, currently in Phase III clinical trials for the treatment of post-operative acute pain.
